Frankfur-Cyntegrity, a German provider of proprietary Risk-based Monitoring (RBM) cloud services for the Life Sciences industry, today announced the roll out of “@RACT-Pro”-simple and affordable risk assessment and mitigation tool. There is even a free version. This online SaaS (software as a service) application is specifically designed for mid-market clinical enterprises and biotech companies transiting to risk-oriented processes in response to the latest revision of the Good Clinical Practice guideline ICH E6 (R2).
“We are thrilled to help the clinical research community bringing high-level regulatory guidance into daily practice. Nowadays, in pharma simple answers matter. How to generate basic documents like Risk Management plan or Risk Register fast and easy? How to leverage the efficiency of project management with artificial intelligence? All areas of clinical trial management will benefit from risk information to make sound decisions. We are happy now to make it affordable for all. There is no excuse any more not to conduct the proper risk management in a clinical trial.”, says Dr. Artem Andrianov, CEO of Cyntegrity.
@RACT-Pro - the Key to Clinical Success and Regulatory Compliance
@RACT-Pro offers all essential features for three main regulatory-required activities
In other words, it introduces to novice users the basics of collaborative Risk-based Quality Management.
“Once clinical monitors and others involved in a clinical study start working with @RACT-Pro they will understand the true value of this service. The built-in intelligence and self-learning aspects of the platform, will help them save time and effort when setting up the next study”, explains Cyntegrity’s Chief Scientific Officer, Dr. Johann Proeve.
Cyntegrity is a leading RBM technology provider, which offers specialized cloud and SaaS solutions for the efficient Risk-based Quality Management and Monitoring in clinical trials. Cyntegrity’s mission is to offer high-quality analytics that are more predictive than retrospective, which have the ability to integrate the knowledge from previous trials with contextual, real-world data to reduce patient-risk and to optimize clinical operations. For more information, visit https://cyntegrity.com.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.